-+ 0.00%
-+ 0.00%
-+ 0.00%

TME Pharma CEO says NOX-A12 partnering talks continue as runway extends into Q2 2027

PUBT·09/16/2026 06:00:39
Listen to the news
TME Pharma CEO says NOX-A12 partnering talks continue as runway extends into Q2 2027
  • TME Pharma CEO Diede van den Ouden reaffirmed confidence in the company’s strategy, with talks continuing on partnering options for NOX-A12.
  • Management kept its focus on securing terms that preserve long-term economics, including a substantial share of peak sales upside.
  • Cost cuts since June 2025 extended the cash runway into Q2 2027, with limited dilution since December 2024 via standard bond financing.
  • Partner discussions center on executing the Phase 2 GLORIA trial under what management described as a robust regulatory strategy.
  • Van den Ouden said the company aims to conclude its assessment phase, with an update once a decision is reached and agreements finalized.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TME Pharma NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160200OMX_____CNEWS_EN_GNW1001262930_en) on September 16, 2026, and is solely responsible for the information contained therein.